TABLE 3.
Zones of inhibition by bacteriocins and antibiotics
| Compound or strain | ZOI (mm) for the following indicator strains: |
|
|---|---|---|
| JRS4/pIB184-Km | IBSA70/pIB184-Km | |
| Lantibiotics | ||
| Smba | 24 ± 1 | 18 ± 1 |
| Haloduracin | 15 ± 1 | 15 ± 1 |
| Galolacticin | 15 ± 1 | 16 ± 1 |
| Nisina | 18 ± 1 | 14 ± 1 |
| Cell wall antibioticsb | ||
| Amdinocillin (AMD10) | 18 ± 1 | 20 ± 1 |
| Bacitracin (B10) | 27 ± 2 | 27 ± 2 |
| Colistin (CL10) | 9 ± 1 | 9 ± 1 |
| Cycloserine (100 mg/ml) | 35 ± 2 | 37 ± 2 |
| Fosfomycin (F300) | 24 ± 2 | 24 ± 2 |
| Penicillin (P2) | 29 ± 1 | 30 ± 1 |
| Polymyxin B (PB300) | 12 ± 1 | 13 ± 1 |
| Tunicamycin (5 mg/ml)a | 19 ± 1 | 13 ± 1 |
| Vancomycin (V5) | 17 ± 1 | 17 ± 1 |
| Strains producing bacteriocin | ||
| UA159 | 18 ± 1 | 17 ± 1 |
| UA159::ΔnlmAB | 15 ± 1 | 15 ± 1 |
| UA159::ΔnlmC | 16 ± 1 | 16 ± 1 |
| UA159::ΔnlmABC | 14 ± 1 | 13 ± 1 |
a
ZOIs shown differ substantially from the wild-type value.
b
The strengths of the antibiotics are shown in parentheses.